Twist Bioscience Expects Q1 2025 Sales Of ~$87M Vs. Consensus Of $84.473M

Benzinga
18 Nov 2024

For the first quarter, Twist expects: Total revenue of approximately $87 million

  • SynBio revenue of approximately $34 million, growth of 26% year over year
  • NGS revenue of approximately $48 million, growth of 22% year over year
  • Biopharma revenue of approximately $5 million

Adjusted EBITDA of approximately $(20) million with sequential improvements throughout 2025

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10